Esophageal Cancer Reagents | abinScience

Home > Featured Products > Oncology Research > Esophageal Cancer

Esophageal cancer includes squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Checkpoint immunotherapy (PD-1) is now first-line, and HER2, FGFR, and Claudin 18.2 are expanding the targeted therapy landscape. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO

Key Biomarkers & Targets

HER2

ErbB2

Amplified in ~15–30% of EAC. T-DXd active in HER2-low disease. 115 products. Validated: Blocking, ELISA, FC, IF, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

PD-L1

CD274

Nivolumab + chemo is first-line for advanced ESCC and EAC. 130 products. Validated: Blocking, ELISA, FC, IF, IHC, WB.

Antibodies • Biosimilars • Proteins

FGFR

Fibroblast Growth Factor Receptor

FGFR2 amplification in EAC; emerging therapeutic target. 76 products. Validated: ELISA, FC, IF, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

Claudin 18.2

CLDN18.2

Expressed in GEJ adenocarcinoma; zolbetuximab-class therapeutics. 44 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

B7-H3 / CD276

Immune Checkpoint

Overexpressed in esophageal SCC; emerging ADC target. 39 products. Validated: ELISA, FC, IHC, WB.

Antibodies • Biosimilars • Proteins

VEGF

Angiogenesis

Anti-angiogenic combination therapy in esophageal cancer. 122 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

EGFR

ErbB1

EGFR pathway activation in esophageal SCC. 108 products. Validated: Blocking, ELISA, FC, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

CEA

CEACAM5

Serum biomarker for esophageal adenocarcinoma monitoring. 103 products. Validated: ELISA, FC, IF, IHC, SPR, WB.

Antibodies • Biosimilars • Proteins

Why Researchers Choose abinScience

IHC-Validated AntibodiesAntibodies with IHC validation available for: HER2, PD-L1, FGFR, CLDN18, B7-H3, VEGF. See individual product pages for clone details and recommended dilutions.

Flow Cytometry ReadyFC-validated antibodies available for: HER2, PD-L1, FGFR, CLDN18, B7-H3, VEGF. Multiple conjugates (FITC, APC, PE, PerCP) offered for select clones.

Research-Grade BiosimilarsBiosimilar-grade reference proteins with ELISA and FACS validation for: HER2, PD-L1, FGFR, CLDN18, B7-H3.

Original Manufacturer PricingDirect-from-manufacturer pricing with no distributor markup. Bulk and custom conjugation options available.

Common Research Applications

IHC-based biomarker detection: We offer IHC-validated antibodies for HER2, PD-L1, FGFR, CLDN18, B7-H3. See product pages for validated species and recommended dilutions.
Flow cytometry immunophenotyping: FC-validated antibodies available for HER2, PD-L1, FGFR, CLDN18, B7-H3. Select clones offered in FITC, APC, PE, and PerCP conjugates.
Functional and blocking assays: Antibodies with blocking/neutralization validation available for: HER2, PD-L1, VEGF, EGFR.
Biosimilar comparability: Research-grade biosimilar proteins (ELISA/FACS/Functional assay validated) available for HER2, PD-L1, FGFR, CLDN18.

Documents & QC Data

Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.

FAQs

What PD-L1 reagents do you offer?

We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).

What VEGF reagents do you offer?

We offer 66 detection antibodies, 39 research-grade biosimilar proteins, and 17 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A169 (ELISA, IHC, WB; unconjugated), YW64.3 (ELISA, FC; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Vesencumab, Navicixizumab, Dilpacimab).

What HER2 reagents do you offer?

We offer 33 detection antibodies, 75 research-grade biosimilar proteins, and 7 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, SPR, WB. Available clones include: A21 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 1A064 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Disitamab, Timigutuzumab, Gancotamab).

What EGFR reagents do you offer?

We offer 45 detection antibodies, 49 research-grade biosimilar proteins, and 14 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: SAA2220 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), 11F8 (ELISA, FC, WB; APC, FITC, PE). Research-grade biosimilar proteins also available (e.g., Modotuximab, Tomuzotuximab, Depatuxizumab).

Can I get custom antibodies for novel targets?

Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.

536 product results for "Esophageal Cancer"